The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype - A link to gastric carcinogenesis

Cancer Letters

Volumn 270, Issue 2, 2008, Pages 218-228

  Venerito, Marino ^a   Kuester, Doerthe ^b   Wex, Thomas ^a   Roessner, Albert ^b   Malfertheiner, Peter ^a   Treiber, Gerhard ^a  

^a Department of Gastroenterology   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

5 Lipoxygenase; Cyclooxygenase 1 and 2; Eradication; H. pylori; Leukotrienes

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ARACHIDONATE 5 LIPOXYGENASE; CLARITHROMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYSTEINYL LEUKOTRIENE RECEPTOR 1; DICLOFENAC; IBUPROFEN; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR 1; LEUKOTRIENE RECEPTOR; METRONIDAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA;

AGED; ANTI-BACTERIAL AGENTS; ARACHIDONATE 5-LIPOXYGENASE; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; RECEPTORS, LEUKOTRIENE; RECEPTORS, LEUKOTRIENE B4; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 52149114678     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.05.015     Document Type: Article

References (42)

1. Malfertheiner P., Megraud F., O'Morain C., Bazzoli F., El-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., and Kuipers E.J. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56 (2007) 772-781
2. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 52 (1992) 6735-6740
3. Peterson W.L. Review article: Helicobacter pylori and gastric adenocarcinoma. Aliment Pharmacol. Ther. 16 Suppl. 1 (2002) 40-46
4. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of GC. N. Engl. J. Med. 345 (2001) 784-789
5. IARC, Schistosomes, liver flukes and Helicobacter pylori, IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Lyon, 7-14 June 1994, IARC Monogr. Eval. Carcinog. Risks Hum. 61 (1994) 1-241.
6. Higham J., Kang J.Y., and Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 50 (2002) 460-464
7. Halter F., Tarnawski A.S., Schmassmann A., et al. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 49 (2001) 443-453
8. Wang W.H., Huang J.Q., Zheng G.F., et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl. Cancer Inst. 95 (2003) 1784-1791
9. Baron J.A., Cole B.F., Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348 (2003) 891-899
10. Rostom A., Dube C., Lewin G., et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Int. Med. 146 (2007) 376-389
11. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (2003) 47-56
12. Treiber G., Wex T., Link A., et al. The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa. Aliment Pharmacol. Ther. 23 (2005) 155-167
13. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
14. Chan A.T., Ogino S., and Fuchs C.S. Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. N. Engl. J. Med. 356 (2007) 2131-2142
15. Romano M., Ricci V., and Zarrilli R. Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis-implications for chemoprevention. Nat. Clin. Pract. Gastroenterol. Hepatol. 3 (2006) 622-632
16. Dixon M.F., Genta R.M., Yardley J.H., et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 20 (1996) 1161-1181
17. Meining A., Kompisch A., and Stolte M. Comparative classification and grading of Helicobacter pylori gastritis in patients with GC and patients with functional dyspepsia. Scand J. Gastroenterol. 38 (2003) 707-711
18. Venerito M., Treiber G., Wex T., et al. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol. Ther. 23 (2006) 1225-1233
19. Peterson W.L. Review article: Helicobacter pylori and gastric adenocarcinoma. Aliment Pharmacol. Ther. 16 Suppl.1 (2002) 40-46
20. Leodolter A., Ebert M.P., Peitz U., et al. Prevalence of H pylori associated "high risk gastritis" for development of GC in patients with normal endoscopic findings. World J. Gastroenterol. 12 (2006) 5509-5512
21. Hojo M., Miwa H., Ohkusa T., et al. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharm. Ther. 16 (2002) 1923-1932
22. Leung W.K., Lin S.R., Ching J.Y., et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 53 (2004) 1244-1249
23. Ito M., Haruma K., Kamada T., et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 16 (2002) 1449-1456
24. Morgner A., Miehlke S., Stolte M., et al. Development of early GC 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. World J. Gastroenterol. 7 (2001) 248-253
25. Wong B.C., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent GC in a high-risk region of China: a randomized controlled trial. JAMA 291 (2004) 187-194
26. Romano M., and Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J. 17 (2003) 1986-1995
27. Haeggstrom J.Z., and Wetterholm A. Enzymes and receptors in the leukotriene cascade. Cell Mol. Life Sci. 59 (2002) 742-753
28. Tong W.G., Ding X.Z., and Adrian T.E. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem. Biophys. Res. Commun. 296 (2002) 942-948
29. Martel-Pelletier J., Lajeunesse D., Reboul P., et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 62 (2003) 501-509
30. Ding X.Z., Hennig R., and Adrian T.E. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol. Cancer 2 (2003) 10-22
31. Sheu B.S., Yang H.B., Sheu S.M., et al. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of GC patients. Clin. Cancer Res. 9 (2003) 5245-5251
32. Wambura C., Aoyama N., Shirasaka D., et al. Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 16 (2004) 969-979
33. Treiber G., Siegle I., and Fritz P. Cox-2 expression is upregulated in intestinal type gastric cancer and preceding neoplastic changes linked to Helicobacter pylori infection. Gastroenterology 120 suppl 1 (2001) A744
34. Karam S.M., Straiton T., Hassan W.M., et al. Defining epithelial cell progenitors in the human oxyntic mucosa. Stem Cells 21 (2003) 322-336
35. Li N., Sood S., Wang S., et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin. Cancer Res. 11 (2005) 2089-2096
36. Chen X., Wang S., Wu N., et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin. Cancer Res. 10 (2004) 6703-6709
37. Ye Y.N., Wu W.K., Shin V.Y., et al. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26 (2005) 827-834
38. Tager A.M., and Luster A.D. BLT-1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot. Essent. Fatty Acids 69 (2003) 123-134
39. Pettersson A., Sabirsh A., Bristulf J., et al. Pro- and anti-inflammatory substances modulate expression of the leukotriene B4 receptor, BLT-1, in human monocytes. J. Leukoc. Biol. 77 (2005) 1018-1025
40. Ohd J.F., Wikstrom K., and Sjolander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 119 (2000) 1007-1018
41. Paruchuri S., Mezhybovska M., Juhas M., et al. Endogenous production of leukotriene D(4) mediates autocrine survival and proliferation via CysLT(1) receptor signalling in intestinal epithelial cells. Oncogene 25 (2006) 6660-6665
42. Mezhybovska M., Wikstrom K., Ohd J.F., et al. Pro-inflammatory mediator leukotriene D4 induces transcriptional activity of potentially oncogenic genes. Biochem. Soc. Trans. 33 (2005) 698-700